Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metolazone in Chronic Kidney Disease
NCT04542304Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metolazone in chronic kidney disease (CKD), end stage renal disease (ESRD), sponsored by Stanford University. Started Mar 2021; status: terminated.
02
Drugs
metolazone
03
Conditions
chronic kidney disease (CKD)end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT04542304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542304.